HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Turns To Meda In Sweden For Open Door Into Consumer Market

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.

You may also be interested in...



Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs

Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.

Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN

Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.

Misbranding Grades Coming For Compliant VMS Labeling If Found Missing From Proposed MPL

Under Senate legislation proposing mandatory listing with FDA for all supplements sold in US, a product labeled in compliance with all other agency regulations would be deemed misbranded if not registered for  proposed list.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

RS123053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel